Nasus Pharma is a clinical-stage, specialty pharmaceutical company developing powder-based formulations that are delivered intranasally. Lead product NS002 uses a dose spray unit to deliver epinephrine for anaphylaxis. It has reported positive topline data & is expected to be the subject of pivotal studies in 4Q:26. Pivotal study results are expected in early 2027 followed by a 505(b)(2) new drug application. The upcoming pivotal trial will seek to show comparability with EpiPen. Nasus has also conducted pivotal studies for NS001, which is a powder-based formulation of naloxone for opioid overdose. Other pipeline assets use its Nasax technology for chemotherapy-induced and post-operative nausea and vomiting as well as metabolic and cardiovascular indications. Epinephrine has been used for over a century as treatment for anaphylaxis & is the active pharmaceutical ingredient (API) used in approved therapies. Nevertheless, injectable epinephrine has notable limitations, including delayed and variable bioavailability, exposure to needles, cumbersome applicator size and short shelf life. NS002 is designed to overcome these drawbacks and has the potential to become the new standard of care for outpatient anaphylaxis management.